<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <title>Template &middot; Bootstrap</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="">

  <!-- Le styles -->
  <link href="../assets/css/bootstrap.css" rel="stylesheet">
  <style type="text/css">
    body {
      padding-top: 20px;
      padding-bottom: 60px;
    }

    /* Custom container */
    .container {
      margin: 0 auto;
      max-width: 1200px;
    }
    .container > hr {
      margin: 60px 0;
    }

    /* Main marketing message and sign up button */
    .jumbotron {
      margin: 80px 0;
      text-align: center;
    }
    .jumbotron h1 {
      font-size: 100px;
      line-height: 1;
    }
    .jumbotron .lead {
      font-size: 24px;
      line-height: 1.25;
    }
    .jumbotron .btn {
      font-size: 21px;
      padding: 14px 24px;
    }

    /* Supporting marketing content */
    .marketing {
      margin: 60px 0;
    }
    .marketing p + h4 {
      margin-top: 28px;
    }


    /* Customize the navbar links to be fill the entire space of the .navbar */
    .navbar .navbar-inner {
      padding: 0;
    }
    .navbar .nav {
      margin: 0;
      display: table;
      width: 100%;
    }
    .navbar .nav li {
      display: table-cell;
      width: 1%;
      float: none;
    }
    .navbar .nav li a {
      font-weight: bold;
      text-align: center;
      border-left: 1px solid rgba(255,255,255,.75);
      border-right: 1px solid rgba(0,0,0,.1);
    }
    .navbar .nav li:first-child a {
      border-left: 0;
      border-radius: 3px 0 0 3px;
    }
    .navbar .nav li:last-child a {
      border-right: 0;
      border-radius: 0 3px 3px 0;
    }
  </style>
  <link href="../assets/css/bootstrap-responsive.css" rel="stylesheet">

  <!-- HTML5 shim, for IE6-8 support of HTML5 elements -->
    <!--[if lt IE 9]>
      <script src="../assets/js/html5shiv.js"></script>
    <![endif]-->

    <!-- Fav and touch icons -->
    <link rel="apple-touch-icon-precomposed" sizes="144x144" href="../assets/ico/apple-touch-icon-144-precomposed.png">
    <link rel="apple-touch-icon-precomposed" sizes="114x114" href="../assets/ico/apple-touch-icon-114-precomposed.png">
    <link rel="apple-touch-icon-precomposed" sizes="72x72" href="../assets/ico/apple-touch-icon-72-precomposed.png">
    <link rel="apple-touch-icon-precomposed" href="../assets/ico/apple-touch-icon-57-precomposed.png">
    <link rel="shortcut icon" href="../assets/ico/favicon.png">
  </head>

  <body>

    <div class="container">

      <div class="masthead">
        <h3 class="muted">Mutation report</h3>
        <div class="navbar">
          <div class="navbar-inner">
            <div class="container">
              <ul class="nav">
                <li class="active"><a href="therapeutic.html" >Therapeutic benefit</a></li>
                <li><a href="drugdrug.html" >Drug-Drug Interaction</a></li>
                <li><a href="drugfood.html">Drug-Food interaction</a></li>
                <li><a href="esmoguide.html">
                  <span style='color: #32502d'>E</span>
                  <span style='color: #6e1e50'>S</span>
                  <span style='color: #7d8232'>M</span>
                  <span style='color: #1f325f'>O</span> guidelines</a></li> 
                  <li><a href="pharmgkb.html">PharmGKB variant</a></li>
                  <li><a href="mutations.html">Mutations associations</a></li>
                  <li><a href="offlabel.html">Off label drug</a></li>
                  <li><a href="cosmic.html">Cosmic Mutations</a></li>
                  <li><a href="reference.html">Reference Details</a></li>
                </ul>
              </div>
            </div>
          </div><!-- /.navbar -->
        </div>



        <div id="detected-variant-therapeutic-benefit" class="section level2 tabset">
          <div name="Detected_variant_therapeutic_benefit" data-unique="Detected_variant_therapeutic_benefit"></div>
          <h2 class="hasAnchor">Detected variant therapeutic benefit<a href="#detected-variant-therapeutic-benefit" class="anchor-section"></a>
          </h2>
          <ul class="nav nav-tabs" role="tablist">
            <li role="presentation" class="active"><a role="tab" data-toggle="tab" href="#variant-mutation" aria-controls="variant-mutation" aria-expanded="true">Variant Mutation</a></li>
            <li role="presentation" class=""><a role="tab" data-toggle="tab" href="#evidence-details" aria-controls="evidence-details" aria-expanded="false">Evidence Details</a></li>
            <li role="presentation" class=""><a role="tab" data-toggle="tab" href="#variant-details" aria-controls="variant-details" aria-expanded="false">Variant Details</a></li>
          </ul>

          <div class="tab-content">
            <div id="variant-mutation" class="section level3 tab-pane tabbed-pane active" role="tabpanel">

              <div class="accordion" id="accordion2">
                <div class="accordion-group">
                  <div class="accordion-heading">
                    <h4>
                      <a class="accordion-toggle" data-toggle="collapse" data-parent="#accordion2" href="#collapseOne">
                        Mutations with clinical evidence
                      </a></h4>
                    </div>
                    <div id="collapseOne" class="accordion-body collapse in">
                      <div class="accordion-inner">



                        <div id="gene-kras" class="section level4">
                          <h4 class="hasAnchor">Gene KRAS<a href="#gene-kras" class="anchor-section"></a></h4>
                          <table class="table table-striped table-hover table-responsive" style="margin-left: auto; margin-right: auto;">
                            <thead>
                              <tr>
                                <th style="text-align:left;">
                                  #
                                </th>
                                <th style="text-align:left;">
                                  Variant
                                </th>
                                <th style="text-align:left;">
                                  Drug
                                </th>
                                <th style="text-align:left;">
                                  Drug Interaction
                                </th>
                                <th style="text-align:left;">
                                  Evidence Type
                                </th>
                                <th style="text-align:left;">
                                  Clinical Significance
                                </th>
                                <th style="text-align:left;">
                                  Evidence Level
                                </th>
                                <th style="text-align:left;">
                                  Details
                                </th>
                                <th style="text-align:left;">
                                  Trials
                                </th>
                                <th style="text-align:left;">
                                  References
                                </th>
                                <th style="text-align:left;">
                                  Approved
                                </th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td style="text-align:left;">
                                  <a id="evi-KRAS-1" name="evi-KRAS-1"></a>1
                                </td>
                                <td style="text-align:left;">
                                  G13D
                                </td>
                                <td style="text-align:left;">
                                  Cetuximab
                                </td>
                                <td style="text-align:left;">
                                </td>
                                <td style="text-align:left;">
                                  Predictive
                                </td>
                                <td style="text-align:left;">
                                  Resistance
                                </td>
                                <td style="text-align:left;">
                                  Clinical evidence
                                </td>
                                <td style="text-align:left;">
                                  [<a href="Javascript:;" class="my_ref_link" data-id="#det-KRAS-1">+</a>]
                                </td>
                                <td style="text-align:left;">
                                </td>
                                <td style="text-align:left;">
                                  <a href="reference.html" class="my_ref_link" data-id="#ref-1">1</a>, <a href="reference.html" class="my_ref_link" data-id="#ref-2">2</a>, <a href="reference.html" class="my_ref_link" data-id="#ref-3">3</a>
                                </td>
                                <td style="text-align:left;">
                                  AIFA/EMA/FDA
                                </td>
                              </tr>
                              <tr>
                                <td style="text-align:left;">
                                  <a id="evi-KRAS-2" name="evi-KRAS-2"></a>2
                                </td>
                                <td style="text-align:left;">
                                  G13D
                                </td>
                                <td style="text-align:left;">
                                  Cetuximab
                                </td>
                                <td style="text-align:left;">
                                </td>
                                <td style="text-align:left;">
                                  Predictive
                                </td>
                                <td style="text-align:left;">
                                  Sensitivity/Response
                                </td>
                                <td style="text-align:left;">
                                  Clinical evidence
                                </td>
                                <td style="text-align:left;">
                                  [<a href="Javascript:;" class="my_ref_link" data-id="#det-KRAS-2">+</a>]
                                </td>
                                <td style="text-align:left;">
                                </td>
                                <td style="text-align:left;">
                                  <a href="reference.html" class="my_ref_link" data-id="#ref-4">4</a>
                                </td>
                                <td style="text-align:left;">
                                  AIFA/EMA/FDA
                                </td>
                              </tr>
                            </tbody>
                          </table>

                        </div>
                      </div>
                    </div>
                  </div>
                </div>
                <div class="accordion-group">
                  <div class="accordion-heading">
                    <h4><a class="accordion-toggle" data-toggle="collapse" data-parent="#accordion2" href="#collapseTwo">
                      Other evidence level
                    </a></h4>
                  </div>
                  <div id="collapseTwo" class="accordion-body collapse">
                    <div class="accordion-inner">

                      <div id="gene-kras" class="section level4">
                        <h4 class="hasAnchor">Gene KRAS<a href="#gene-kras" class="anchor-section"></a></h4>
                        <table class="table table-striped table-hover table-responsive" style="margin-left: auto; margin-right: auto;">
                          <thead>
                            <tr>
                              <th style="text-align:left;">
                                #
                              </th>
                              <th style="text-align:left;">
                                Variant
                              </th>
                              <th style="text-align:left;">
                                Drug
                              </th>
                              <th style="text-align:left;">
                                Drug Interaction
                              </th>
                              <th style="text-align:left;">
                                Evidence Type
                              </th>
                              <th style="text-align:left;">
                                Clinical Significance
                              </th>
                              <th style="text-align:left;">
                                Evidence Level
                              </th>
                              <th style="text-align:left;">
                                Details
                              </th>
                              <th style="text-align:left;">
                                Trials
                              </th>
                              <th style="text-align:left;">
                                References
                              </th>
                              <th style="text-align:left;">
                                Approved
                              </th>
                            </tr>
                          </thead>
                          <tbody>

                            <tr>
                              <td style="text-align:left;">
                                <a id="evi-KRAS-3" name="evi-KRAS-3"></a>3
                              </td>
                              <td style="text-align:left;">
                                G13D
                              </td>
                              <td style="text-align:left;">
                                Cetuximab
                              </td>
                              <td style="text-align:left;">
                              </td>
                              <td style="text-align:left;">
                                Predictive
                              </td>
                              <td style="text-align:left;">
                                No Responsive
                              </td>
                              <td style="text-align:left;">
                                Late trials
                              </td>
                              <td style="text-align:left;">
                                [<a href="Javascript:;" class="my_ref_link" data-id="#det-KRAS-3">+</a>]
                              </td>
                              <td style="text-align:left;">
                              </td>
                              <td style="text-align:left;">
                                <a href="reference.html" class="my_ref_link" data-id="#ref-5">5</a>
                              </td>
                              <td style="text-align:left;">
                                AIFA/EMA/FDA
                              </td>
                            </tr>
                            <tr>
                              <td style="text-align:left;">
                                <a id="evi-KRAS-4" name="evi-KRAS-4"></a>4
                              </td>

                              <td style="text-align:left;">
                                G13D
                              </td>
                              <td style="text-align:left;">
                                Panitumumab, Cetuximab
                              </td>
                              <td style="text-align:left;">
                                Substitutes
                              </td>
                              <td style="text-align:left;">
                                Predictive
                              </td>
                              <td style="text-align:left;">
                                Resistance
                              </td>
                              <td style="text-align:left;">
                                Case study
                              </td>
                              <td style="text-align:left;">
                                [<a href="Javascript:;" class="my_ref_link" data-id="#det-KRAS-4">+</a>]
                              </td>
                              <td style="text-align:left;">
                              </td>
                              <td style="text-align:left;">
                                <a href="reference.html" class="my_ref_link" data-id="#ref-6">6</a>
                              </td>
                              <td style="text-align:left;">
                                AIFA/EMA/FDA, 
                                AIFA/EMA/FDA
                              </td>
                            </tr>
                            <tr>
                              <td style="text-align:left;">
                                <a id="evi-KRAS-5" name="evi-KRAS-5"></a>5
                              </td>
                              <td style="text-align:left;">
                                G13D
                              </td>
                              <td style="text-align:left;">
                                Cetuximab
                              </td>
                              <td style="text-align:left;">
                              </td>
                              <td style="text-align:left;">
                                Predictive
                              </td>
                              <td style="text-align:left;">
                                Resistance
                              </td>
                              <td style="text-align:left;">
                                Preclinical evidence
                              </td>
                              <td style="text-align:left;">
                                [<a href="Javascript:;" class="my_ref_link" data-id="#det-KRAS-5">+</a>]
                              </td>
                              <td style="text-align:left;">
                              </td>
                              <td style="text-align:left;">
                                <a href="reference.html" class="my_ref_link" data-id="#ref-7">7</a>
                              </td>
                              <td style="text-align:left;">
                                AIFA/EMA/FDA
                              </td>
                            </tr>
                            <tr>
                              <td style="text-align:left;">
                                <a id="evi-KRAS-6" name="evi-KRAS-6"></a>6
                              </td>
                              <td style="text-align:left;">
                                G13D
                              </td>
                              <td style="text-align:left;">
                                Cetuximab
                              </td>
                              <td style="text-align:left;">
                              </td>
                              <td style="text-align:left;">
                                Predictive
                              </td>
                              <td style="text-align:left;">
                                Sensitivity/Response
                              </td>
                              <td style="text-align:left;">
                                Preclinical evidence
                              </td>
                              <td style="text-align:left;">
                                [<a href="Javascript:;" class="my_ref_link" data-id="#det-KRAS-6">+</a>]
                              </td>
                              <td style="text-align:left;">
                              </td>
                              <td style="text-align:left;">
                                <a href="reference.html" class="my_ref_link" data-id="#ref-4">4</a>
                              </td>
                              <td style="text-align:left;">
                                AIFA/EMA/FDA
                              </td>
                            </tr>
                            <tr>
                              <td style="text-align:left;">
                                <a id="evi-KRAS-7" name="evi-KRAS-7"></a>7
                              </td>
                              <td style="text-align:left;">
                                G13D
                              </td>
                              <td style="text-align:left;">
                                Dactolisib, Selumetinib
                              </td>
                              <td style="text-align:left;">
                                Combination
                              </td>
                              <td style="text-align:left;">
                                Predictive
                              </td>
                              <td style="text-align:left;">
                                Sensitivity/Response
                              </td>
                              <td style="text-align:left;">
                                Preclinical evidence
                              </td>
                              <td style="text-align:left;">
                                [<a href="Javascript:;" class="my_ref_link" data-id="#det-KRAS-7">+</a>]
                              </td>
                              <td style="text-align:left;">
                              </td>
                              <td style="text-align:left;">
                                <a href="reference.html" class="my_ref_link" data-id="#ref-8">8</a>
                              </td>
                              <td style="text-align:left;">
                                AIFA/EMA/FDA
                              </td>
                            </tr>
                            <tr>
                              <td style="text-align:left;">
                                <a id="evi-KRAS-8" name="evi-KRAS-8"></a>8
                              </td>
                              <td style="text-align:left;">
                                G13D
                              </td>
                              <td style="text-align:left;">
                                Regorafenib
                              </td>
                              <td style="text-align:left;">
                              </td>
                              <td style="text-align:left;">
                                Predictive
                              </td>
                              <td style="text-align:left;">
                                Resistance
                              </td>
                              <td style="text-align:left;">
                                Preclinical evidence
                              </td>
                              <td style="text-align:left;">
                                [<a href="Javascript:;" class="my_ref_link" data-id="#det-KRAS-8">+</a>]
                              </td>
                              <td style="text-align:left;">
                              </td>
                              <td style="text-align:left;">
                                <a href="reference.html" class="my_ref_link" data-id="#ref-9">9</a>
                              </td>
                              <td style="text-align:left;">
                                FDA, Not approved
                              </td>
                            </tr>
                          </tbody>
                        </table>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
              <div id="evidence-details" class="section level3 tab-pane tabbed-pane" role="tabpanel">
                <div id="gene-kras-1" class="section level4">
                  <h4 class="hasAnchor">Gene KRAS<a href="#gene-kras-1" class="anchor-section"></a></h4>
                  <table class="table table-striped table-hover table-responsive" style="margin-left: auto; margin-right: auto;">
                    <thead>
                      <tr>
                        <th style="text-align:left;">
                          #
                        </th>
                        <th style="text-align:left;">
                          Evidence Statement
                        </th>
                        <th style="text-align:left;">
                          References
                        </th>
                        <th style="text-align:left;">
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr class="highlight">
                        <td style="text-align:left;">
                          <a id="det-KRAS-1" name="det-KRAS-1"></a>1
                        </td>
                        <td style="text-align:left;">
                          In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS. 12 patients with KRAS G13D mutant, metastatic colorectal cancer were treated with single agent cetuximab in a prospective phase II study. The primary endpoint of the trial was 4-month progression-free survival, with a benefit to treatment evaluated to be 50% of patients were progression free at this point. None of 12 patients achieved response by RECIST 1.1 criteria and three patients (25%) were progression-free at 4 months, with disease control rate at 6 months reaching 0%. Median PFS and OS were 1.9 (95% CI 1.7<e2>&lt;80&gt;&lt;93&gt;3.8) and 7.2 months (95% CI 5.7<e2>&lt;80&gt;&lt;93&gt;9.7). Meta-analysis encompassing eight randomized controlled trials (n = 5967) for assessment of both overall survival (OS) and progression-free survival (PFS) of patients with KRAS mutant metastatic colorectal cancer. For other KRAS MT the hazard ratio for OS benefit with addition of anti-EGFR mAb therapy was 1.06 (95% confidence interval [CI]; 0.96, 1.17), compared to 1.08 (95% CI; 0.73, 1.60) for KRAS G13D [test for interaction p=0.99]. In contrast, the hazard ratio for KRAS wild-type (WT) tumours was 0.85 (95% CI; 0.76, 0.95). Regarding PFS benefit with anti-EGFR mAbs, the hazard ratio was 1.07 (95% CI; 0.92, 1.26) for other KRAS MT, 0.96 (95% CI; 0.73, 1.27) for KRAS G13D, and 0.68 (95% CI; 0.54, 0.85) for KRAS wild-type. Again, the test for interaction (p=0.46) demonstrated no significant difference in PFS benefit for anti-EGFR mAb therapy between KRAS G13D and other KRAS MT. </e2></e2>
                        </td>
                        <td style="text-align:left;">
                          <a href="Javascript:;" class="my_ref_link" data-id="#ref-1">1</a>, <a href="Javascript:;" class="my_ref_link" data-id="#ref-2">2</a>, <a href="Javascript:;" class="my_ref_link" data-id="#ref-3">3</a>
                        </td>
                        <td style="text-align:left;">
                          [<a href="Javascript:;" class="my_ref_link" data-id="#evi-KRAS-1">-</a>]
                        </td>
                      </tr>
                      <tr>
                        <td style="text-align:left;">
                          <a id="det-KRAS-2" name="det-KRAS-2"></a>2
                        </td>
                        <td style="text-align:left;">
                          KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS.
                        </td>
                        <td style="text-align:left;">
                          <a href="Javascript:;" class="my_ref_link" data-id="#ref-4">4</a>
                        </td>
                        <td style="text-align:left;">
                          [<a href="Javascript:;" class="my_ref_link" data-id="#evi-KRAS-2">-</a>]
                        </td>
                      </tr>
                      <tr>
                        <td style="text-align:left;">
                          <a id="det-KRAS-3" name="det-KRAS-3"></a>3
                        </td>
                        <td style="text-align:left;">
                          RAS mutations predict lack of response to epidermal growth factor receptor monoclonal antibody therapy in patients with metastatic colorectal cancer (mCRC), but preclinical studies and retrospective clinical data suggest that patients with tumors harboring the exon 2 KRAS G13D mutation may benefit from cetuximab. We aimed to assess cetuximab monotherapy and cetuximab plus irinotecan in patients with molecularly selected (G13D mutation) chemotherapy-refractory mCRC in a randomized phase II trial of this rare molecular subtype. Patients with chemotherapy-refractory KRAS G13D mutation-positive mCRC who had progressed within 6 months of irinotecan therapy were randomly assigned to cetuximab 400 mg/m(2) loading dose and then 250 mg/m(2) once per week with or without irinotecan 180 mg/m(2) once every 2 weeks. The primary end point was 6-month progression-free survival; secondary end points were response rate, overall survival, quality of life, and toxicity. Fifty-one of 53 patients recruited over 2 years were eligible. The 6-month progression-free survival rate was 10% (95% CI, 2% to 26%) for cetuximab versus 23% (95% CI, 9% to 40%) for cetuximab plus irinotecan with a hazard ratio of 0.74 (95% CI, 0.42 to 1.32). Response and stable disease rates were 0% and 58% for monotherapy versus 9% and 70% for combination treatment, respectively. Overall survival and quality of life were similar; toxicities were higher with combination therapy. In patients with G13D-mutated chemotherapy-refractory mCRC, there was no statistically significant improvement in disease control at 6 months with either cetuximab monotherapy or cetuximab plus irinotecan. No responses were seen with single-agent cetuximab. The responses observed with the combination of cetuximab and irinotecan may reflect true drug synergy or persistent irinotecan sensitivity. The ICECREAM (Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Among Patients with a G13D Mutation) study demonstrates the need to prospectively evaluate hypotheses that were previously supported by retrospective analyses and exemplifies the value of international collaboration in trials of rare molecular subtypes.
                        </td>
                        <td style="text-align:left;">
                          <a href="Javascript:;" class="my_ref_link" data-id="#ref-5">5</a>
                        </td>
                        <td style="text-align:left;">
                          [<a href="Javascript:;" class="my_ref_link" data-id="#evi-KRAS-3">-</a>]
                        </td>
                      </tr>
                      <tr>
                        <td style="text-align:left;">
                          <a id="det-KRAS-4" name="det-KRAS-4"></a>4
                        </td>
                        <td style="text-align:left;">
                          In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G13D was the only variant noted in the primary rectal tumor of one patient who experienced disease progression following treatment (Patient 45; Supplemental Table 1). This is response is consistent with observations made of the larger cohort, where patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant. However, two other patients (37 and 47; Table S1) had G13D as their only noted variant, but experienced partial response.
                        </td>
                        <td style="text-align:left;">
                          <a href="Javascript:;" class="my_ref_link" data-id="#ref-6">6</a>
                        </td>
                        <td style="text-align:left;">
                          [<a href="Javascript:;" class="my_ref_link" data-id="#evi-KRAS-4">-</a>]
                        </td>
                      </tr>
                      <tr>
                        <td style="text-align:left;">
                          <a id="det-KRAS-5" name="det-KRAS-5"></a>5
                        </td>
                        <td style="text-align:left;">
                          In an in vitro study, a Lim1215 colorectal cancer cell line endogenously expressing KRAS G13D mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild-type KRAS. Resistance was determined by assessing cell viability.
                        </td>
                        <td style="text-align:left;">
                          <a href="Javascript:;" class="my_ref_link" data-id="#ref-7">7</a>
                        </td>
                        <td style="text-align:left;">
                          [<a href="Javascript:;" class="my_ref_link" data-id="#evi-KRAS-5">-</a>]
                        </td>
                      </tr>
                      <tr>
                        <td style="text-align:left;">
                          <a id="det-KRAS-6" name="det-KRAS-6"></a>6
                        </td>
                        <td style="text-align:left;">
                          Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.
                        </td>
                        <td style="text-align:left;">
                          <a href="Javascript:;" class="my_ref_link" data-id="#ref-4">4</a>
                        </td>
                        <td style="text-align:left;">
                          [<a href="Javascript:;" class="my_ref_link" data-id="#evi-KRAS-6">-</a>]
                        </td>
                      </tr>
                      <tr>
                        <td style="text-align:left;">
                          <a id="det-KRAS-7" name="det-KRAS-7"></a>7
                        </td>
                        <td style="text-align:left;">
                          In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, PIK3CA or BRAF mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 mice harbored KRAS mutations including 5 G13D mutations where disease stabilization was achieved in 2/5 mice treated with AZD6244 or combination therapy and 0/5 mice treated with BEZ235 alone.
                        </td>
                        <td style="text-align:left;">
                          <a href="Javascript:;" class="my_ref_link" data-id="#ref-8">8</a>
                        </td>
                        <td style="text-align:left;">
                          [<a href="Javascript:;" class="my_ref_link" data-id="#evi-KRAS-7">-</a>]
                        </td>
                      </tr>
                      <tr>
                        <td style="text-align:left;">
                          <a id="det-KRAS-8" name="det-KRAS-8"></a>8
                        </td>
                        <td style="text-align:left;">
                          In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G13D mutation demonstrated resistance to regorafenib treatment (IC50: 172.23 nM vs. 114.28 nM, P&lt;0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G13D is more resistant to regorafenib than KRAS wt, but more sensitive than common KRAS G12 mutations.
                        </td>
                        <td style="text-align:left;">
                          <a href="Javascript:;" class="my_ref_link" data-id="#ref-9">9</a>
                        </td>
                        <td style="text-align:left;">
                          [<a href="Javascript:;" class="my_ref_link" data-id="#evi-KRAS-8">-</a>]
                        </td>
                      </tr>
                    </tbody>
                  </table>
                </div>
              </div><div id="variant-details" class="section level3 tab-pane tabbed-pane" role="tabpanel">

                <div id="gene-kras-2" class="section level4">
                  <h4 class="hasAnchor">Gene KRAS<a href="#gene-kras-2" class="anchor-section"></a></h4>
                  <table class="table table-striped table-hover table-responsive" style="margin-left: auto; margin-right: auto;">
                    <thead>
                      <tr>
                        <th style="text-align:left;">
                          Variant
                        </th>
                        <th style="text-align:left;">
                          Chromosome
                        </th>
                        <th style="text-align:left;">
                          Ref_base
                        </th>
                        <th style="text-align:left;">
                          Var_base
                        </th>
                        <th style="text-align:left;">
                          Start
                        </th>
                        <th style="text-align:left;">
                          Stop
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td style="text-align:left;">
                          G13D
                        </td>
                        <td style="text-align:left;">
                          chr12
                        </td>
                        <td style="text-align:left;">
                          C
                        </td>
                        <td style="text-align:left;">
                          T
                        </td>
                        <td style="text-align:left;">
                          25245347
                        </td>
                        <td style="text-align:left;">
                          25245347
                        </td>
                      </tr>
                    </tbody>
                  </table>
                  <table class="table table-striped table-hover table-responsive" style="margin-left: auto; margin-right: auto;">
                    <thead>
                      <tr>
                        <th style="text-align:left;">
                          Variant
                        </th>
                        <th style="text-align:left;">
                          Variant_summary
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td style="text-align:left;">
                          G13D
                        </td>
                        <td style="text-align:left;">
                          While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.
                        </td>
                      </tr>
                    </tbody>
                  </table>
                </div>
              </div></div>


            </div>
          </div>


<!-- 
      <ul class="nav nav-tabs" role="tablist"><li role="presentation" class="active"><a role="tab" data-toggle="tab" href="#variant-mutation" aria-controls="variant-mutation" aria-expanded="true">Variant Mutation</a></li><li role="presentation" class=""><a role="tab" data-toggle="tab" href="#evidence-details" aria-controls="evidence-details" aria-expanded="false">Evidence Details</a></li><li role="presentation" class=""><a role="tab" data-toggle="tab" href="#variant-details" aria-controls="variant-details" aria-expanded="false">Variant Details</a></li></ul>
      <div class="accordion" id="accordion2">
        <div class="accordion-group">
          <div class="accordion-heading">
            <a class="accordion-toggle" data-toggle="collapse" data-parent="#accordion2" href="#collapseOne">
              Mutations with clinical evidence
            </a>
          </div>
          <div id="collapseOne" class="accordion-body collapse in">
            <div class="accordion-inner">
              Anim pariatur cliche...
            </div>
          </div>
        </div>
        <div class="accordion-group">
          <div class="accordion-heading">
            <a class="accordion-toggle" data-toggle="collapse" data-parent="#accordion2" href="#collapseTwo">
              Other evidence level
            </a>
          </div>
          <div id="collapseTwo" class="accordion-body collapse">
            <div class="accordion-inner">
              Anim pariatur cliche...
            </div>
          </div>
        </div>
      </div>
    -->


    <!-- Le javascript
      ================================================== -->
      <!-- Placed at the end of the document so the pages load faster -->
      <script src="../assets/js/jquery.js"></script>
      <script src="../assets/js/bootstrap-transition.js"></script>
      <script src="../assets/js/bootstrap-alert.js"></script>
      <script src="../assets/js/bootstrap-modal.js"></script>
      <script src="../assets/js/bootstrap-dropdown.js"></script>
      <script src="../assets/js/bootstrap-scrollspy.js"></script>
      <script src="../assets/js/bootstrap-tab.js"></script>
      <script src="../assets/js/bootstrap-tooltip.js"></script>
      <script src="../assets/js/bootstrap-popover.js"></script>
      <script src="../assets/js/bootstrap-button.js"></script>
      <script src="../assets/js/bootstrap-collapse.js"></script>
      <script src="../assets/js/bootstrap-carousel.js"></script>
      <script src="../assets/js/bootstrap-typeahead.js"></script>
      <script type="text/javascript">
        $(function() {
          $(window).load(function() {
            $('.show-all-start').each(function() {
              var t=$(this);
              t.find('a[role="tab"]').each(function () { $(this).click(); });
              t.find('a[role="tab"]').first().click();
            });
            
            $('a.my_ref_link').click(function () {
              var t = $(this), id=t.data('id'), o=$(id);
              o.parent().parent().addClass('highlight').siblings().removeClass('highlight');
              var tabId = o.closest('.tab-pane').attr('id');
              console.log(tabId);
              o.closest('.tabset').find('a[href="#'+tabId+'"]').click()
              console.log(o.closest('.tabset').find('a[href="#'+tabId+'"]'));
              $('body').scrollTo(id)
            });
          });
        });
      </script>

    </body>
    </html>
